RxDoctor Payments Data

Amar Raval

Urology · Palm Harbor, FLNPI 1346530755

Payments from drug & device makers

$60,488in general payments, 2019–2025

Across 762 payments — averaging $79.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$34K
  • Medtronic$6K
  • Coloplast$4K
  • Johnson & Johnson$3K
  • Axonics, Inc.$2K
  • Neotract Inc.$2K
  • plus $9K from 47 others

What the payments were for

  • Consulting fees$35,36858%
  • Speaking & faculty fees$2,4734%
  • Travel & lodging$2,0953%
  • Food & beverage$20,13733%
  • Education$4141%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,488 in reported general payments places this provider in the 85th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$343,829
Medicare patients
575
Services billed
9,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide35$515,243
GemtesaVibegron122$110,057
MyrbetriqMirabegron104$95,038
OrgovyxRelugolix31$79,150
Solifenacin Succinate107$6,031
Tamsulosin Hcl508$5,576
Testosterone30$5,174
Testosterone Cypionate73$4,891
Estradiol81$3,995
OsphenaOspemifene12$2,805
Alfuzosin Hcl ErAlfuzosin Hcl127$2,770
Finasteride168$1,794
Oxybutynin Chloride64$1,729
Dutasteride22$1,518
Potassium Citrate ErPotassium Citrate19$1,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$411$610,282139 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$622$189,207153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 urology providers in Florida.

Other urology in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →